Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/35484511http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/35484511http://www.w3.org/2000/01/rdf-schema#comment"

Objective

Glioma was the most common type of intracranial malignant tumor. Even after standard treatment, the recurrence and malignant progression of lower-grade gliomas (LGGs) were almost inevitable. The overall survival (OS) of patients with LGG varied widely, making it critical for prognostic prediction. Small G Protein Signaling Modulator 1 (SGSM1) has hardly been studied in gliomas. Therefore, we aimed to investigate the prognostic role of SGSM1 and its relationship with immune infiltration in LGGs.

Methods

We obtained RNA sequencing data from The Cancer Genome Atlas (TCGA) to analyze SGSM1 expression. Functional enrichment analyses, immune infiltration analyses, immune checkpoint analyses, and clinicopathology analyses were performed. Univariate and multivariate Cox regression analyses were used to identify independent prognostic factors. And nomogram model has been developed. Kaplan-Meier survival analysis and log-rank test were used to estimate the relationship between OS and SGSM1 expression. The survival analyses and Cox regression were validated in datasets from the Chinese Glioma Genome Atlas (CGGA).

Results

SGSM1 was significantly down-regulated in LGGs. Functional enrichment analyses revealed SGSM1 was correlated with immune response. Most immune cells and immune checkpoints were negatively correlated with SGSM1 expression. The Kaplan-Meier analyses showed that low SGSM1 expression was associated with a poor outcome in LGG and its subtypes. The Cox regression showed SGSM1 was an independent prognostic factor in patients with LGG (HR = 0.494, 95%CI = 0.311-0.784, P = 0.003).

Conclusion

SGSM1 was considered to be a new prognostic biomarker for patients with LGG. And our study provided a potential therapeutic target for LGG treatment."xsd:string
http://purl.uniprot.org/citations/35484511http://purl.org/dc/terms/identifier"doi:10.1186/s12885-022-09548-7"xsd:string
http://purl.uniprot.org/citations/35484511http://purl.uniprot.org/core/author"Ding Y."xsd:string
http://purl.uniprot.org/citations/35484511http://purl.uniprot.org/core/author"Li J."xsd:string
http://purl.uniprot.org/citations/35484511http://purl.uniprot.org/core/author"Wang J."xsd:string
http://purl.uniprot.org/citations/35484511http://purl.uniprot.org/core/author"Wang W."xsd:string
http://purl.uniprot.org/citations/35484511http://purl.uniprot.org/core/author"Zhao J."xsd:string
http://purl.uniprot.org/citations/35484511http://purl.uniprot.org/core/date"2022"xsd:gYear
http://purl.uniprot.org/citations/35484511http://purl.uniprot.org/core/name"BMC Cancer"xsd:string
http://purl.uniprot.org/citations/35484511http://purl.uniprot.org/core/pages"466"xsd:string
http://purl.uniprot.org/citations/35484511http://purl.uniprot.org/core/title"Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas."xsd:string
http://purl.uniprot.org/citations/35484511http://purl.uniprot.org/core/volume"22"xsd:string
http://purl.uniprot.org/citations/35484511http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/35484511
http://purl.uniprot.org/citations/35484511http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/35484511
http://purl.uniprot.org/uniprot/#_A0A087X241-mappedCitation-35484511http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35484511
http://purl.uniprot.org/uniprot/#_Q2NKQ1-mappedCitation-35484511http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35484511
http://purl.uniprot.org/uniprot/Q2NKQ1http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/35484511
http://purl.uniprot.org/uniprot/A0A087X241http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/35484511